Neogen Corporation Interest Expense
Neogen Corporation (NEOG) reported Interest Expense of $24.10 million for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-07-30
- Neogen Corporation interest expense for the quarter ending 2024-05-31 was $10.79M, a 9.28% increase year-over-year.
- Neogen Corporation interest expense for the quarter ending 2024-02-29 was $10.50M, a 15.91% increase year-over-year.
- Neogen Corporation interest expense for the quarter ending 2023-11-30 was $10.27M, a 23.30% increase year-over-year.
- Neogen Corporation interest expense for the quarter ending 2023-08-31 was $10.60M.
- Neogen Corporation interest expense for fiscal 2026 was $24.10M, a 36.75% decline from fiscal 2025.
- Neogen Corporation interest expense for fiscal 2025 was $38.10M, a 9.61% decline from fiscal 2024.
- Neogen Corporation interest expense for fiscal 2024 was $42.15M, a 54.66% increase from fiscal 2023.
- Neogen Corporation interest expense for fiscal 2023 was $27.25M.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | $24.10M 10-K · filed 2026-07-30 | |||||||
| 2025-05-31 | $38.10M 10-K · filed 2026-07-30 | $38.12M 10-K · filed 2025-07-30 | ||||||
| 2024-05-31 | $10.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-30 | $21.28M derived: sum of 2 quarters · filed 2025-07-30 | $31.55M derived: sum of 3 quarters · filed 2025-07-30 | $42.15M 10-K · filed 2025-07-30 | ||||
| 2024-02-29 | $10.50M 10-Q · filed 2024-04-09 | $20.76M derived: sum of 2 quarters · filed 2024-04-09 | $31.36M 10-Q · filed 2024-04-09 | $41.24M derived: sum of 4 quarters · filed 2024-07-30 | ||||
| 2023-11-30 | $10.27M 10-Q · filed 2024-01-09 | $20.87M 10-Q · filed 2024-01-09 | $30.74M derived: sum of 3 quarters · filed 2024-07-30 | $39.80M derived: sum of 4 quarters · filed 2024-07-30 | ||||
| 2023-08-31 | $10.60M 10-Q · filed 2023-10-10 | $20.47M derived: sum of 2 quarters · filed 2024-07-30 | $29.53M derived: sum of 3 quarters · filed 2024-07-30 | $37.85M derived: sum of 4 quarters · filed 2024-07-30 | ||||
| 2023-05-31 | $9.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $18.93M derived: sum of 2 quarters · filed 2024-07-30 | $27.25M derived: sum of 3 quarters · filed 2024-07-30 | $27.25M 10-K · filed 2024-07-30 | ||||
| 2023-02-28 | $9.06M 10-Q · filed 2024-04-09 | $9.10M 10-Q · filed 2023-04-04 | $17.38M derived: sum of 2 quarters · filed 2024-04-09 | $17.38M 10-Q · filed 2024-04-09 | $17.40M 10-Q · filed 2023-04-04 | |||
| 2022-11-30 | $8.33M 10-Q · filed 2024-01-09 | $8.33M 10-Q · filed 2024-01-09 | $8.50M 10-Q · filed 2023-01-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |